Anna Jo Bodurtha Smith

Anna Jo Bodurtha Smith

Auto-generated profile, based on publicly available information

Anna Jo Bodurtha Smith

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania Health Systems, Philadelphia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
ASAnna Jo Bodurtha Smith
Anna Jo Bodurtha Smith
AFAmanda Nickles Fader
Amanda Nickles Fader
ETEdward J. Tanner
Edward J. Tanner

1 March 2013 in Pediatrics
Verified
Journal Article
Closed access
PDF file
ASAnna Jo Smith
Anna Jo Smith
ÁSÁine Skow
Áine Skow
JBJoann Bodurtha
Joann Bodurtha
SKSanjay Kinra
Sanjay Kinra
BACKGROUND AND OBJECTIVES: Childhood obesity is a major problem in the United States, yet screening and treatment are often inaccessible or ineffective. Health information technology (IT) may improve the quality, efficiency, and reach of chronic disease management. The objective of this study was to review the effect of health IT (electronic health records [EHRs], telemedicine, text message or telephone support) on patient outcomes and care processes in pediatric obesity management. METHODS: Medline, Embase, and the Cochrane Registry of Controlled Trials were searched from January 2006 to April 2012. Controlled trials, before-and-after studies, and cross-sectional studies were included if they used IT to deliver obesity screening or treatment to children aged 2 to 18 and reported impact on patient outcomes (BMI, dietary or physical activity behavior change) or care processes (BMI screening, comorbidity testing, diet, or physical activity counseling). Two independent reviewers extracted data and assessed trial quality. RESULTS: Thirteen studies met inclusion criteria. EHR use was associated with increased BMI screening rates in 5 of 8 studies. Telemedicine counseling was associated with changes in BMI percentile similar to that of in-person counseling and improved treatment access in 2 studies. Text message or telephone support was associated with weight loss maintenance in 1 of 3 studies. CONCLUSIONS: To date, health IT interventions have improved access to obesity treatment and rates of screening. However, the impact on weight loss and other health outcomes remains understudied and inconsistent. More interactive and time-intensive interventions may enhance health IT's clinical effectiveness in chronic disease management.

1 May 2016 in International Journal of Women's Health
Verified
Journal Article
Open access
PDF file
AFAmanda Nickles Fader
Amanda Nickles Fader
ABAnna L Beavis
Anna L Beavis
ASAnna Jo Bodurtha Smith
Anna Jo Bodurtha Smith
Modifiable lifestyle factors, such as obesity, lack of physical activity, and smoking, contribute greatly to cancer and chronic disease morbidity and mortality worldwide. This review appraises recent evidence on modifiable lifestyle factors in the prevention of endometrial cancer (EC) and ovarian cancer (OC) as well as new evidence for lifestyle management of EC and OC survivors. For EC, obesity continues to be the strongest risk factor, while new evidence suggests that physical activity, oral contraceptive pills, and bariatric surgery may be protective against EC. Other medications, such as metformin and nonsteroidal anti-inflammatory drugs, may be protective, and interventional research is ongoing. For OC, we find increasing evidence to support the hypothesis that obesity and hormone replacement therapy increase the risk of developing OC. Oral contraceptive pills are protective against OC but are underutilized. Dietary factors such as the Mediterranean diet and alcohol consumption do not seem to affect the risk of either OC or EC. For EC and OC survivors, physical activity and weight loss are associated with improved quality of life. Small interventional trials show promise in increasing physical activity and weight maintenance for EC and OC survivors, although the impact on long-term health, including cancer recurrence and overall mortality, is unknown. Women’s health providers should integrate counseling about these modifiable lifestyle factors into both the discussion of prevention for all women and the management of survivors of gynecologic cancers.

27 April 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
GCGeorge T Capone
George T Capone
MSMary Stephens
Mary Stephens
SSStephanie Santoro
Stephanie Santoro
BCBrian Chicoine
Brian Chicoine
PBPeter Bulova
Peter Bulova
DWDown Syndrome Medical Interest Group (DSMIG‐USA) Adult Health Workgroup
Down Syndrome Medical Interest Group (DSMIG‐USA) Adult Health Workgroup

1 November 2016 in Academic Pediatrics
Verified
Journal Article
Closed access
ASAnna Jo Smith
Anna Jo Smith
ETElizabeth L. Turner
Elizabeth L. Turner
SKSanjay Kinra
Sanjay Kinra

5 January 2022 in Obstetrics & Gynecology
Verified
Journal Article
Open access
ASAnna Jo Bodurtha Smith
Anna Jo Bodurtha Smith
DPDaniella Pena
Daniella Pena
EKEmily Ko
Emily Ko
With 102,000 new cases of gynecologic cancer, 30,000 associated deaths annually, and increasing rates of endometrial cancer, gynecologic cancer is a growing problem. Although gynecologic cancer care has advanced significantly in the past decade owing to new therapeutics and specialized training in radical surgery, even insured women face major barriers to accessing and affording quality gynecologic cancer care. This commentary reviews current literature on insurance-mediated disparities in gynecologic cancer and provides education to clinicians on barriers to care. One third of women with a gynecologic cancer never see a gynecologic oncologist. Up to 40% of Medicare Advantage plans lack an in-network gynecologic oncologist, and 33% of private insurance plans do not include an in-network National Cancer Institute-accredited cancer center, limiting access to surgical advances and clinical trials. Women with Medicaid insurance and gynecologic cancer are 25% less likely to receive guideline-concordant care. Among insured women, 50% experience financial toxicity during gynecologic cancer treatment, and costs may be even higher for certain Medicare enrollees. Addressing these insurance-mediated disparities will be important to help our patients fully benefit from the scientific advances in our field and thrive after a gynecologic cancer diagnosis.